T cell injection targeting CD7 chimeric antigen receptor
PG-CART-07-001 (1)
Phase 1 mab active
Quick answer
T cell injection targeting CD7 chimeric antigen receptor for CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies is a Phase 1 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
- Phase
- Phase 1
- Modality
- mab
- Status
- active